Lan Jiang

US Patent:

20210017171, Jan 21, 2021

Filed:

Jun 26, 2020

Appl. No.:

16/914209

Inventors:

- South San Francisco CA, US
Chengguo DONG - Staten Island NY, US
Timothy HOM - Sunnyvale CA, US
Lan JIANG - Foster City CA, US
Katerina LEFTHERIS - San Mateo CA, US
Hui LI - Santa Clara CA, US
Manuel MUNOZ - Vallejo CA, US
Maureen REILLY - Burlingame CA, US
Yajun ZHENG - Foster City CA, US

International Classification:

C07D 471/04
C07D 519/00

Abstract:

The invention relates to compounds of formula (A) and formula (I):or a salt thereof, wherein R, R, R, R, R, R, R, R, R, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

US Patent:

20200352942, Nov 12, 2020

Filed:

Apr 8, 2020

Appl. No.:

16/843824

Inventors:

- South San Francisco CA, US
Chengguo DONG - Staten Island NY, US
Timothy HOM - Sunnyvale CA, US
Lan JIANG - Foster City CA, US
Katerina LEFTHERIS - San Mateo CA, US
Hui LI - Santa Clara CA, US
Manuel MUNOZ - Vallejo CA, US
Maureen REILLY - Burlingame CA, US
Yajun ZHENG - Foster City CA, US
Martin DECARIS - Oakland CA, US
Scott TURNER - Oakland CA, US

International Classification:

A61K 31/5025
A61K 31/502
A61K 31/4375
A61K 9/00
A61P 11/00

Abstract:

The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I):or a salt thereof, wherein R, R, R, R, R, R, R, R, R, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

US Patent:

20200113476, Apr 16, 2020

Filed:

Dec 10, 2019

Appl. No.:

16/708857

Inventors:

Lan Jiang - DALLAS TX, US

International Classification:

A61B 5/055
G06T 7/00
G06T 7/33
G06T 7/35
G16H 50/30
G16H 30/20
G06F 17/18

Abstract:

A method for precision cancer treatment by identifying drug resistance is provided. In some embodiments, the method may include: detecting tumor oxygenated perfusion by having a patient breathe air to acquire MRI baseline data; inhalation of hyperoxia gas to generate higher than baseline HbOblood circulating in body to acquire MRI enhanced data; the region-of-interest (ROI), which in this case is a tumor volume (V), and which may be performed by volume contour tracing/region-of-interest (ROI) analysis and 3D tumor volumetry methods; calculating voxel's enhanced signal intensity (ΔSI); calculating tumor oxygenated perfusion percentage (OPP %); selecting different threshold and calculating maps such as a reconstruction OPP % pseudo color map; calculating tumor volume change ratio (Vt %); overlaying reconstruction OPP % pseudo color map to original images for visualizing tumor response data; drawing or plotting the OPP % and Vt % on a cancer treatment response information diagram, and identifying the type of drug resistance, classifying the drug resistance being caused by poor drug distribution factor or cells-specific factor based on pooled collected data.

US Patent:

20190276449, Sep 12, 2019

Filed:

Mar 7, 2019

Appl. No.:

16/296194

Inventors:

- South San Francisco CA, US
Chengguo DONG - Staten Island NY, US
Timothy HOM - Sunnyvale CA, US
Lan JIANG - Foster City CA, US
Katerina LEFTHERIS - San Mateo CA, US
Hui LI - Santa Clara CA, US
Manuel MUNOZ - Vallejo CA, US
Maureen REILLY - Burlingame CA, US
Yajun ZHENG - Foster City CA, US

International Classification:

C07D 471/04
C07D 519/00

Abstract:

The invention relates to compounds of formula (A) and formula (I):or a salt thereof, wherein R, R, R, R, R, R, R, R, R, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

US Patent:

20170091409, Mar 30, 2017

Filed:

Sep 26, 2016

Appl. No.:

15/275897

Inventors:

Lan Jiang - DALLAS TX, US

International Classification:

G06F 19/00

Abstract:

A cancer therapeutic window evaluation method is provided. In some embodiments, the method may comprise: detecting tumor oxygenated perfusion by having a patient breathe air to acquire MRI baseline data; inhalation of hyperoxia gas to generate higher than baseline HbOblood circulating in body to acquire MRI enhanced data; the region-of-interest (ROI), which in this case is a tumor volume (V), and which may be performed by volume contour tracing/region-of-interest (ROI) analysis and 3D tumor volumetry methods; calculating voxel's enhanced signal intensity (ΔSI); calculating tumor oxygenated perfusion percentage (OPP %); selecting different threshold and calculating maps such as a reconstruction OPP % pseudo color map; calculating tumor volume change ratio (Vt %); overlaying reconstruction OPP % pseudo color map to original images for visualizing tumor response data; drawing or plotting the OPP % and Vt % may on a cancer treatment evaluation diagram, and calculating risk/benefit analysis based on pooled collected data.